Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells

BIOLOGICAL2 trials

Sponsors

Fujian Medical University, First Affiliated Hospital of Zhejiang University

Conditions

Diffuse Large B Cell LymphomaRelapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive

Phase 1

Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma

Fujian Medical UniversityRelapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive

Start: 2019-12-31End: 2024-12-31Target: 18Updated: 2020-01-02

An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection

First Affiliated Hospital of Zhejiang UniversityDiffuse Large B Cell Lymphoma

Start: 2020-07-25End: 2022-06-25Target: 18Updated: 2020-08-26